Study of Healthy Cohort for Early Detection of Cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05193305

Enrollment

10000

Registered

2022-01-14

Start date

2023-02-01

Completion date

2043-02-28

Last updated

2026-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

Cancer produces a significant burden on society with a majority diagnosed at late stages when the chance of cure is low. Early diagnosis improves patient outcomes. Data consisting of lifestyle factors, medications, physical activity, years before conventional cancer diagnosis is also worthwhile for to determine early detection. This is only achievable with longitudinal tracking of a large number of healthy individuals and identifying those who do develop cancer over time.

Detailed description

To conduct a longitudinal cohort study of patients who do not have a malignancy at the time of enrollment and are followed over a 20 year period to see if patients develop a malignancy and associate clinical and lifestyle factors as well as collection of blood. All adults 18 years of age and older undergoing upper or lower endoscopy for routine medical care will be eligible for this study.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* All adults 18 years of age of older undergoing upper or lower endoscopy for routine medical care.

Exclusion criteria

* Persons with current malignancy * Persons with history of malignancy and treatment within last 5 years of enrollment, excluding non-melanoma skin cancer or cervical in-situ. * Persons who are unable or unwilling to provide repeat blood samples and complete follow-up questionnaires * Persons who lack the capacity to provide consent * Persons who do not speak English * Persons who are visually or hearing impaired.

Design outcomes

Primary

Measure	Time frame	Description
Development of malignancy	Up to 20 years	Assessment of participants for the development of malignancy during a 20-year follow-up period.

Secondary

Measure	Time frame	Description
Development of biomarkers	Up to 20 years	To identify proteins, RNA and DNA that have changes in expression in those who develop cancer.

Countries

United States

Contacts

CONTACTElham Afghani

eafghan1@jhmi.edu410-955-5000

PRINCIPAL_INVESTIGATORElham Afghani

Johns Hopkins University

Outcome results